CSBio CSBio

X
[{"orgOrder":0,"company":"Mnemo Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mnemo Banks $90M to Tackle Barriers in CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mnemo Therapeutics"},{"orgOrder":0,"company":"Argobio","sponsor":"Oncode Bridge Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncode Institute and ArgoBio Launch Laigo Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Argobio"},{"orgOrder":0,"company":"Transgene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Scraps Transgene Pact in Blow to Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Transgene"},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mablink Bioscience Enters an Agreement to be Acquired by Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Mablink Bioscience"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,483.0 million","upfrontCash":"$26.6 million","newsHeadline":"Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Innate Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the collaboration, Sanofi exercised one option to license a new ANKET® (antibody-based NK cell engager therapeutics) platform from Innate, for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.

            Lead Product(s): Antibody-based NK Cell Engager Therapeutic

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $1,483.0 million Upfront Cash: $26.6 million

            Deal Type: Licensing Agreement December 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Eli lilly expands its portfolio of antibody-drug conjugates for cancer by gaining Mablink’s existing pipeline and proprietary PSARLink™ technology, an innovative hydrophilic linker which holds potential for broadening the therapeutic index of ADCs.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the termination, Transgene will regain the global rights to the intravenous oncolytic virus drug candidate, developed using Transgene’s next-generation viral Invir.IO™ platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination May 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Oncode Bridge Fund

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding February 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center.

            Lead Product(s): CAR-T Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $90.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY